Summary
Syros Pharmaceuticals Inc (Syros) is a life sciences company that develops medicines for the treatment of cancer, immune-mediated diseases, and other diseases. The company’s services include gene regulation, new medicines development, genes control, proprietary drug development platform, integrated gene control assay technologies, and computational biology, chemistry, and deep biologic insights solutions. It also provides research and drug development, identifying disease and patient-targeted gene control medicines, therapeutics solutions, differential gene control maps construction, new molecular targets solutions, gene control compounds, and patient lives transformation, among others. Syros’s gene control platform identifies novel gene control targets linked to genomically defined patient populations, and drugging gene control targets. Syros is headquartered in Cambridge, Massachusetts, the US.
Syros Pharmaceuticals Inc (SYRS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Syros Pharma Raises USD40 Million in Venture Financing 11
Syros Pharma Raises USD53 Million in Series B Venture Financing 13
Syros Pharma Raises US$30 Million In Series A Financing 15
LS22 Raises USD1.25 Million in Venture Financing 16
Partnerships 17
Syros Pharma Enters into Research Agreement 17
Licensing Agreements 18
Syros Pharma Enters into Licensing Agreement with TMRC 18
Syros Pharma Enters into Licensing Agreement with Whitehead Institute 19
Syros Pharma Enters into Licensing Agreement with Dana-Farber and Whitehead 21
Syros Pharma Enters into Licensing Agreement with Dana-Farber Cancer Institute 23
Equity Offering 25
Syros Pharma Raises USD57.5 Million in IPO 25
Syros Pharmaceuticals Inc - Key Competitors 27
Key Employees 28
Locations And Subsidiaries 29
Head Office 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30
List of Tables
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 1
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Syros Pharmaceuticals Inc, Deals By Therapy Area, 2010 to YTD 2016 8
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Syros Pharma Raises USD40 Million in Venture Financing 11
Syros Pharma Raises USD53 Million in Series B Venture Financing 13
Syros Pharma Raises US$30 Million In Series A Financing 15
LS22 Raises USD1.25 Million in Venture Financing 16
Syros Pharma Enters into Research Agreement 17
Syros Pharma Enters into Licensing Agreement with TMRC 18
Syros Pharma Enters into Licensing Agreement with Whitehead Institute 19
Syros Pharma Enters into Licensing Agreement with Dana-Farber and Whitehead 21
Syros Pharma Enters into Licensing Agreement with Dana-Farber Cancer Institute 23
Syros Pharma Raises USD57.5 Million in IPO 25
Syros Pharmaceuticals Inc, Key Competitors 27
Syros Pharmaceuticals Inc, Key Employees 28
List of Figures
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Syros Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8